Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Overview
Vivos Therapeutics Inc is a specialized medical technology company dedicated to addressing sleep disordered breathing (SDB) with a focus on mild-to-moderate obstructive sleep apnea (OSA). Leveraging industry-specific technology and customized oral appliance therapy, the company offers a non-surgical, non-invasive, and low-cost solution that distinguishes it within the competitive landscape of sleep health and medical devices. Key industry terms such as "obstructive sleep apnea", "sleep disordered breathing", and "oral appliance therapy" underscore its commitment to innovative clinical solutions.
Business Model and Operations
The company operates through two core revenue streams. One stream involves the development, commercialization, and direct distribution of customized oral appliances that integrate proprietary clinical protocols. These protocols, often administered by specially trained dentists in collaboration with other healthcare professionals, provide an alternative therapy to traditional CPAP treatments. The second stream is driven by the company’s licensing of its intellectual property, allowing third-party manufacturers to produce therapeutic devices according to the specialized Vivos System guidelines.
Clinical Protocols and Healthcare Integration
At the heart of Vivos Therapeutics is its Vivos System, a treatment protocol that combines device customization with targeted clinical methodologies. Through its integrated healthcare network, the company connects general dentists, medical doctors, myofunctional therapists, and chiropractors, creating a collaborative ecosystem focused on treating SDB. This structure not only facilitates patient access to specialized care but also supports the standardization of care practices within the field of sleep medicine.
Innovation and Industry Positioning
Vivos Therapeutics distinguishes itself by emphasizing non-surgical and non-pharmaceutical approaches to managing OSA. Its focus on low-cost, patient-centric treatment solutions aims to enhance accessibility and compliance, contributing to its competitive positioning against conventional therapies such as CPAP devices. The company’s ongoing efforts to refine its treatment methodologies and expand its integrated network underscore its commitment to clinical excellence and technological advancement.
Research and Development Focus
Innovation remains central to Vivos Therapeutics' strategy. The development of customizable treatment protocols and proprietary oral appliances represents a blend of technical expertise and clinical insight. The company’s research and development efforts not only drive its product offerings forward but also position it as a key contributor within the sleep health arena. By collaborating with clinical experts and leveraging insights from real-world healthcare practices, Vivos continually refines its approach to meet evolving patient needs.
Market and Competitive Landscape
Operating within the broader medical device industry, Vivos Therapeutics faces the dual challenge of technological advancement and regulatory compliance. Its focus on offering a tangible alternative to surgical and pharmaceutical interventions sets it apart. Competitors may include traditional CPAP providers and other oral appliance manufacturers; however, Vivos’ integrated clinical protocols and licensing model offer a unique value proposition that enhances its industry credibility. The company’s strategy to work closely with an array of healthcare providers also reinforces its role as a pivotal player in specialized sleep disorder treatment.
Conclusion
In summary, Vivos Therapeutics Inc provides a distinct approach to managing mild-to-moderate OSA through the use of custom oral appliances and an integrated treatment protocol. Its operations, characterized by dual revenue pathways and a comprehensive healthcare network, illustrate a robust business model suited for the evolving landscape of sleep medicine. This detailed look at its operations, innovation practices, and market positioning provides investors and industry observers with a clear understanding of its core competencies and strategic framework.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its first-quarter financial results for 2021 on May 17, 2021, after market close. A conference call is scheduled for the same day at 5:00 PM ET, where the company will discuss its financial performance and growth strategy. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA). Their Vivos System has been effective for over 15,000 patients worldwide through customized oral appliances.
Vivos Therapeutics, Inc. (VVOS) announced the closing of its public offering of 4,600,000 shares of common stock, including 600,000 additional shares underwriters purchased. The offering price was set at $6.00 per share, leading to gross proceeds of $27.6 million before expenses. Roth Capital Partners served as the sole book-running manager, while National Securities Corporation and Craig-Hallum Capital Group were co-managers. The SEC declared the registration statement effective on May 6, 2021, and the final prospectus was filed on May 10, 2021.
Vivos Therapeutics, Inc. (Nasdaq: VVOS) announced the pricing of a follow-on public offering of 4,000,000 shares of its common stock at $6.00 per share, aiming for gross proceeds of $24 million before deductions. The offering includes a 45-day option for underwriters to buy an additional 600,000 shares. Roth Capital Partners is the sole book-running manager for the offering. The Securities and Exchange Commission (SEC) has declared effective registration statements, and a final prospectus will be filed with the SEC. Investors are encouraged to read the prospectus for complete information.
Vivos Therapeutics (NASDAQ: VVOS) announced the appointment of Dr. Mimi Guarneri as Medical Director of Clinical Education, effective April 1, 2021. Dr. Guarneri is a renowned Integrative Cardiologist, board-certified in multiple specialties, and a founder of The Academy of Integrative Health and Medicine. Her role will focus on promoting the Vivos Medical Integration Division, leveraging her expertise to enhance physician awareness of Vivos’ innovative treatments for obstructive sleep apnea (OSA). The company aims to improve patient outcomes with its non-invasive Vivos System, already utilized by over 1,200 dentists worldwide.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Emerging Growth Conference on April 14, 2021, at 9:00 am EDT. The presentation will be led by CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew.
Investors can register for a free spectator pass. Vivos specializes in treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA), offering the innovative Vivos System, which is a non-invasive solution already benefiting over 15,000 patients worldwide.
Vivos Therapeutics (NASDAQ: VVOS) has announced the launch of MyoCorrect, a telemedicine service offering orofacial myofunctional therapy (OMT) to enhance the treatment of obstructive sleep apnea (OSA). This initiative aims to provide Vivos-trained providers with greater access to OMT, expected to drive additional revenue through increased Vivos System cases and service fees. Vivos anticipates that MyoCorrect will strengthen its competitive positioning in the OSA market, as trained dentists report numerous benefits from integrating OMT into their treatment protocols.
Vivos Therapeutics reported a 15% revenue increase for full year 2020, reaching $13.1 million, up from $11.4 million in 2019. The fourth quarter revenue hit $3.3 million with a gross profit of $2.7 million, marking an 81% gross margin. Despite a net loss of $12.1 million for the full year, the company surpassed 15,000 cases treated. Financial resilience was aided by a $21.6 million IPO in December 2020. New product launches, including AireO2 and VivoScore, are expected to enhance their market position.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 11:40 am Eastern Time. The conference runs from March 24-25, 2021. Key presenters include CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Vivos focuses on innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA), using non-invasive methods. Interested investors can register for a free spectator pass via the provided link.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced plans to release its financial results for Q4 and the full year ended December 31, 2020, after market close on March 25, 2021. The company will hold a conference call at 5:00 p.m. ET to discuss the results and its growth strategy. Vivos aims to provide innovative treatments for sleep-disordered breathing, specifically mild-to-moderate obstructive sleep apnea (OSA), with its Vivos System oral appliances, proven effective in over 15,000 patients. The company is committed to growth through improved treatment technologies.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q1 Virtual Investor Summit on March 23, 2021, at 1:30 PM ET. Key executives, including CEO Kirk Huntsman and CFO Brad Amman, will discuss the company's focus on innovative treatments for sleep-disordered breathing, particularly obstructive sleep apnea (OSA). The Vivos System offers a non-invasive, personalized therapy for patients, which has successfully treated over 15,000 patients globally. Interested investors can register for the presentation and access a replay afterward on Vivos' website.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
What is the core focus of Vivos Therapeutics Inc?
How does the company generate its revenue?
What is the Vivos System?
Who are the primary beneficiaries of Vivos Therapeutics' services?
What distinguishes Vivos Therapeutics from traditional CPAP therapies?
How does Vivos Therapeutics integrate with the healthcare ecosystem?
What market challenges does Vivos Therapeutics face?
How does Vivos Therapeutics demonstrate industry expertise?
